亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study

蛋白尿 医学 不利影响 内科学 贝伐单抗 肾脏疾病 肾病科 回顾性队列研究 泌尿科 肾 化疗
作者
Shigeki Kataoka,Yoshitaka Nishikawa,Taro Funakoshi,Takahiro Horimatsu,Minoru Sakuragi,Eiichiro Uchino,Shusuke Hiragi,Shinya Yamamoto,Kaoru Sakai,Takeshi Matsubara,Motoko Yanagita,Manabu Muto
出处
期刊:International Journal of Clinical Oncology [Springer Science+Business Media]
卷期号:29 (4): 398-406 被引量:5
标识
DOI:10.1007/s10147-024-02474-7
摘要

Background Proteinuria is a common adverse event observed during treatment with antivascular endothelial growth factor (VEGF) antibodies. Proteinuria is a risk factor for renal dysfunction and cardiovascular complications in patients with chronic kidney disease. However, the association between anti-VEGF antibody-induced proteinuria and renal dysfunction or cardiovascular complications remains unclear. Methods The medical records of patients treated with bevacizumab (BV) at Kyoto University Hospital (Kyoto, Japan) between January 2006 and March 2018 were retrospectively reviewed. Adverse event rates were compared between patients who developed qualitative ≥ 2 + proteinuria and those who developed < 1 + proteinuria. Adverse events were defined as renal dysfunction (i.e., ≥ 57% decrease in the eGFR, compared to the rate at the initial treatment) and hospitalization due to BV-associated cardiovascular complications and other adverse events. Results In total, 734 patients were included in this analysis. Renal dysfunction was more common in patients with ≥ 2 + proteinuria than in those with < 1 + proteinuria (13/199, 6.5% vs. 13/535, 2.4%). Seven of these 13 patients with ≥ 2 + proteinuria had transient reversible renal dysfunction. Only four (2.0%) patients had BV-associated renal dysfunction. Of the 734 patients, 6 patients, 16 patients, and 13 patients were hospitalized because of the adverse events of cardiovascular complications, thromboembolisms, and cerebrovascular complications, respectively. No relationship was observed between these adverse events and proteinuria. Conclusion BV treatment-induced proteinuria was not associated with renal dysfunction or other adverse events. Continuing BV with caution is a possible treatment option, even after proteinuria develops, in patients with cancer and a limited prognosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer的应助被符聪采纳,获得10
4秒前
CAOHOU的应助被浮云采纳,获得10
17秒前
29秒前
35秒前
RONG发布了新的文献求助10
42秒前
宇是眼中星眸完成签到 ,获得积分10
1分钟前
研友_nxw2xL完成签到,获得积分0
1分钟前
molihuakai的应助被渟柠采纳,获得10
1分钟前
1分钟前
1分钟前
渟柠发布了新的文献求助10
1分钟前
1分钟前
2分钟前
Blynn发布了新的文献求助30
2分钟前
2分钟前
2分钟前
Blynn完成签到,获得积分10
2分钟前
nojego完成签到,获得积分10
2分钟前
原子超人完成签到,获得积分10
2分钟前
2分钟前
符聪发布了新的文献求助10
3分钟前
寂寞的汽车完成签到,获得积分10
3分钟前
缥缈雯完成签到,获得积分10
3分钟前
3分钟前
舒适鸣凤的应助被369ninja采纳,获得10
3分钟前
3分钟前
再睡一夏发布了新的文献求助10
3分钟前
DATATA完成签到 ,获得积分10
3分钟前
3分钟前
舒适鸣凤的应助被369ninja采纳,获得10
3分钟前
被风吹过的路的应助被369ninja采纳,获得10
4分钟前
4分钟前
再睡一夏完成签到,获得积分10
4分钟前
oleskarabach完成签到,获得积分20
4分钟前
Tim完成签到,获得积分10
4分钟前
舒适鸣凤的应助被369ninja采纳,获得10
4分钟前
庾傀斗发布了新的文献求助10
4分钟前
LuXiaoyu的应助被369ninja采纳,获得10
4分钟前
开心惜梦完成签到,获得积分10
4分钟前
LuXiaoyu的应助被369ninja采纳,获得10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195122
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872905
捐赠科研通 7795112
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609